文献速递心脑血管急症重症综合管理与镇静镇痛消化、代谢与肾脏急症

持续高渗盐水(20% NaCl)对创伤性脑损伤后肾脏结局的影响:COBI 试验的事后分析

Impact of continuous hypertonic (NaCl 20%) saline solution on renal outcomes after traumatic brain injury (TBI): a post hoc analysis of the COBI trial.
PubMed 文献 · Crit Care · 2023-01-27
一句话结论中重度创伤性脑损伤患者持续输注20%高渗盐水维持血钠150–155 mmol/L,虽氯化物摄入显著增加,但未增加KDIGO 2–3期急性肾损伤发生率。

该研究为COBI试验的事后分析,纳入9个ICU收治的370例中重度创伤性脑损伤患者,干预组持续输注高渗盐水维持血钠150–155 mmol/L至少48小时,对照组按最新脑创伤基金会指南治疗,主要终点为入组28天内KDIGO 2–3期急性肾损伤。排除缺失数据后322例纳入分析,干预组前4天氯化物摄入量显著更高(97.3 ± 31.6 g vs 61.3 ± 38.1 g,p < 0.001),第4天血氯更高(117.9 ± 10.7 mmol/L vs 111.6 ± 9 mmol/L,p < 0.001)。急性肾损伤发生率两组无统计学差异(24.5% vs 28.9%,p = 0.45)。作者认为该研究未能证实氯化物负荷对ICU患者肾功能存在潜在不利影响。

要点

  • 中重度创伤性脑损伤患者持续输注20%高渗盐水维持血钠150–155 mmol/L至少48小时,急性肾损伤(KDIGO 2–3期)发生率为24.5%,对照组为28.9%,差异无统计学意义(p = 0.45)。
  • 干预组前4天氯化物摄入量显著高于对照组(97.3 ± 31.6 g vs 61.3 ± 38.1 g,p < 0.001),第4天血氯水平也显著更高(117.9 ± 10.7 mmol/L vs 111.6 ± 9 mmol/L,p < 0.001)。
  • 该事后分析共纳入322例患者(来自COBI试验370例中排除缺失数据后),主要终点为入组28天内KDIGO 2–3期急性肾损伤。
  • 作者结论认为,尽管氯化物摄入显著增加,持续输注高渗盐水并未增加中重度创伤性脑损伤患者的急性肾损伤风险。

适用人群与场景

  • 9个参与ICU收治的中重度创伤性脑损伤患者(COBI试验人群),事后分析排除缺失数据后纳入322例。

诊断标准与关键阈值

  • 急性肾损伤定义:KDIGO分期2期或3期。
  • 干预目标:维持血钠水平在150–155 mmol/L,持续至少48小时。

处置流程与药物剂量

  • 干预组:持续输注20%高渗盐水,以维持血钠150–155 mmol/L至少48小时。
  • 对照组:按最新脑创伤基金会指南推荐治疗。

研究设计与关键结果

  • 研究类型:COBI试验的事后分析,纳入9个ICU的370例中重度创伤性脑损伤患者,排除缺失数据后322例纳入分析。
  • 干预组前4天氯化物摄入量显著高于对照组(97.3 ± 31.6 g vs 61.3 ± 38.1 g,p < 0.001)。
  • 第4天血氯水平干预组显著高于对照组(117.9 ± 10.7 mmol/L vs 111.6 ± 9 mmol/L,p < 0.001)。
  • 主要终点:入组28天内KDIGO 2–3期急性肾损伤发生率干预组24.5% vs 对照组28.9%,差异无统计学意义(p = 0.45)。

证据类型、等级与局限

  • 证据类型:随机对照试验(COBI试验)的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该研究未能证实氯化物负荷对ICU患者肾功能存在潜在不利影响;在中重度创伤性脑损伤患者中,持续输注高渗盐水维持血钠150–155 mmol/L未增加急性肾损伤风险。

指南或共识出处

  • COBI试验(ClinicalTrials.gov注册号NCT03143751,注册日期2017年5月8日)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: To evaluate if the increase in chloride intake during a continuous infusion of 20% hypertonic saline solution (HSS) is associated with an increase in the incidence of acute kidney injury (AKI) compared to standard of care in traumatic brain injury patients.

METHODS: In this post hoc analysis of the COBI trial, 370 patients admitted for a moderate-to-severe TBI in the 9 participating ICUs were enrolled. The intervention consisted in a continuous infusion of HSS to maintain a blood sodium level between 150 and 155 mmol/L for at least 48 h. Patients enrolled in the control arm were treated as recommended by the latest Brain Trauma foundation guidelines. The primary outcome of this study was the occurrence of AKI within 28 days after enrollment. AKI was defined by stages 2 or 3 according to KDIGO criteria.

RESULTS: After exclusion of missing data, 322 patients were included in this post hoc analysis. The patients randomized in the intervention arm received a significantly higher amount of chloride during the first 4 days (intervention group: 97.3 ± 31.6 g vs. control group: 61.3 ± 38.1 g; p < 0.001) and had higher blood chloride levels at day 4 (117.9 ± 10.7 mmol/L vs. 111.6 ± 9 mmol/L, respectively, p < 0.001). The incidence of AKI was not statistically different between the intervention and the control group (24.5% vs. 28.9%, respectively; p = 0.45).

CONCLUSIONS: Despite a significant increase in chloride intake, a continuous infusion of HSS was not associated with AKI in moderate-to-severe TBI patients. Our study does not confirm the potentially detrimental effect of chloride load on kidney function in ICU patients.

TRIAL REGISTRATION: The COBI trial was registered on clinicaltrial.gov (Trial registration number: NCT03143751, date of registration: 8 May 2017).

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Huet O, Chapalain X, Vermeersch V, et al. Impact of continuous hypertonic (NaCl 20%) saline solution on renal outcomes after traumatic brain injury (TBI): a post hoc analysis of the COBI trial. Crit Care. 2023. PMID: 36707841. doi:10.1186/s13054-023-04311-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。